Brought to you by 
Bausch & Lomb gets option to Mimetogen's Phase II dry eye syndrome candidate; option period has expired
05 Nov 2015
Executive Summary
Eye health giant Bausch & Lomb Inc., which is in the process of being acquired by Valeant Pharmaceuticals International Inc. for $8.7bn, has received an option to license exclusive worldwide rights to the Phase II dry eye syndrome (DES) candidate MIMD3 from Mimetogen Pharmaceuticals Inc.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bausch & Lomb gets option to Mimetogen's Phase II dry eye syndrome candidate; option period has expired
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice